Your browser is no longer supported. Please, upgrade your browser.
Cyclo Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.02 Insider Own6.90% Shs Outstand6.36M Perf Week-16.40%
Market Cap50.69M Forward P/E- EPS next Y-1.93 Insider Trans8.68% Shs Float5.66M Perf Month1.44%
Income-8.90M PEG- EPS next Q-0.63 Inst Own7.90% Short Float2.44% Perf Quarter-25.41%
Sales0.90M P/S56.32 EPS this Y19.70% Inst Trans-14.69% Short Ratio0.25 Perf Half Y-32.44%
Book/sh5.06 P/B1.53 EPS next Y-96.90% ROA-156.40% Target Price- Perf Year-60.24%
Cash/sh1.96 P/C3.96 EPS next 5Y- ROE-566.80% 52W Range3.40 - 23.50 Perf YTD78.16%
Dividend- P/FCF- EPS past 5Y-4.30% ROI- 52W High-67.02% Beta-0.98
Dividend %- Quick Ratio3.80 Sales past 5Y-1.00% Gross Margin91.90% 52W Low127.94% ATR0.71
Employees8 Current Ratio3.80 Sales Q/Q-50.00% Oper. Margin- RSI (14)47.89 Volatility9.04% 9.31%
OptionableNo Debt/Eq0.01 EPS Q/Q41.00% Profit Margin- Rel Volume0.08 Prev Close7.97
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume561.66K Price7.75
Recom2.00 SMA203.40% SMA50-9.27% SMA200-22.09% Volume45,367 Change-2.76%
Apr-27-21 09:05AM  
Apr-20-21 09:25AM  
Mar-25-21 08:35AM  
Mar-15-21 08:05AM  
Mar-12-21 08:05AM  
Mar-10-21 08:35AM  
Mar-09-21 09:05AM  
Mar-04-21 09:10AM  
Mar-01-21 09:05AM  
Feb-22-21 09:00AM  
Feb-09-21 08:05AM  
Jan-26-21 08:00AM  
Jan-05-21 08:00AM  
Dec-22-20 02:30PM  
Dec-12-20 02:01AM  
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ostronic Francis PatrickDirectorApr 16Buy6.5310,00065,25076,559Apr 16 01:10 PM
Hrynkow Sharon HemondChief Scientific OfficerMar 29Buy7.461,0007,46018,350Mar 30 01:25 PM
Fine Joshua MChief Financial OfficerMar 29Buy7.405037016,900Mar 30 01:25 PM
Sieger MarkusDirectorMar 29Buy8.1010,00081,00067,614Mar 30 01:26 PM
TATE JEFFREYChief Operating OfficerMar 29Buy7.502,00015,00027,160Mar 30 01:24 PM
Ostronic Francis PatrickDirectorMar 29Buy7.533,00022,60061,559Mar 30 01:24 PM
Sieger MarkusDirectorJan 26Buy6.602,20114,52757,614Jan 27 08:36 AM
Sieger MarkusDirectorJan 25Buy6.307,79949,10855,413Jan 27 08:36 AM